MacroGenics (MGNX) Stock Rating Lowered by Zacks Investment Research

MacroGenics (NASDAQ:MGNX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, January 3rd.

According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

Several other research analysts also recently commented on MGNX. Wedbush reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of MacroGenics in a report on Monday, September 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 price objective on shares of MacroGenics in a report on Tuesday, September 12th. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. Citigroup raised their price target on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Friday, November 10th. Finally, ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.10.

Shares of MacroGenics (NASDAQ MGNX) traded down $0.23 during mid-day trading on Wednesday, hitting $19.45. 127,100 shares of the stock traded hands, compared to its average volume of 147,050. MacroGenics has a 12 month low of $14.36 and a 12 month high of $22.31. The stock has a market cap of $724.67, a price-to-earnings ratio of -4.33 and a beta of 2.73.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. During the same quarter in the previous year, the business earned ($0.97) EPS. The company’s revenue for the quarter was down 48.5% on a year-over-year basis. equities research analysts expect that MacroGenics will post -0.7 EPS for the current year.

In other news, SVP Jon Marc Wigginton sold 10,000 shares of MacroGenics stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the sale, the senior vice president now directly owns 40,000 shares of the company’s stock, valued at approximately $800,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its position in MacroGenics by 8.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,181,317 shares of the biopharmaceutical company’s stock worth $21,831,000 after purchasing an additional 96,900 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in shares of MacroGenics by 43.9% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 10,200 shares during the period. Granite Point Capital Management L.P. purchased a new position in shares of MacroGenics in the third quarter valued at about $756,000. Pinnacle Associates Ltd. increased its position in shares of MacroGenics by 38.3% in the third quarter. Pinnacle Associates Ltd. now owns 843,175 shares of the biopharmaceutical company’s stock valued at $15,582,000 after acquiring an additional 233,657 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of MacroGenics by 56.9% in the third quarter. Dimensional Fund Advisors LP now owns 283,517 shares of the biopharmaceutical company’s stock valued at $5,239,000 after acquiring an additional 102,778 shares during the period. Institutional investors own 85.77% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://ledgergazette.com/2018/01/12/zacks-investment-research-downgrades-macrogenics-mgnx-to-sell.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply